KPTI Earnings Prediction
The chart below shows how KPTI performed 10 days before and after its earnings report, based on data from the past quarters. Typically, KPTI sees a +9.53% change in stock price 10 days leading up to the earnings, and a +0.42% change 10 days following the report. On the earnings day itself, the stock moves by -5.47%. This data can give you a slight idea of what to expect for the next quarter's release.
KPTI Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
38.78M
7.70%
-9.36%
Gross Margin
96.65%
-0.84%
0.07%
Operating Margin
-67.77%
-21.93%
3.12%
Net Margin
-82.70%
-13.70%
-248.71%
EPS
-0.26
-13.33%
-273.33%
No Data Available
KPTI Earnings Analysis
Karyopharm Therapeutics Inc. Corporation (KPTI.O) Earnings Conference Call
Positive
XPOVIO Revenue Increase: XPOVIO one product revenue was $29.5 million, up 5% compared to our results in the second quarter.
Quarterly Revenue Growth: We are very pleased with our third consecutive quarter-over-quarter growth of XPOVIO U.S. revenues amid a highly competitive market place and are well on track to deliver in the upper half of the guidance outlined at the start of the year.
Market Launch Potential: Our established commercial organization is well set up to potentially drive successful and rapid launches in myelofibrosis and endometrial cancer.
Strong Demand Growth: We achieved strong demand growth quarter over quarter in the community where XPOVIO tends to be used as a convenient or manageable option for patients as an earlier line of therapy or if the patients are unable to access a T-cell therapy.
Cost-Saving Initiatives Impact: We expect our 2025 operating expenses to be lower than 2024 as we recognize the full-year benefits of our ongoing cost-saving initiatives.
Negative
Quarterly Revenue Comparison: Total revenue for the third quarter of 2024 was $38.8 million, compared to $36 million for the third quarter of 2023, indicating a modest growth but not meeting expectations.
Revenue Decline Analysis: Net U.S. XPOVIO revenue for the third quarter of 2024 was $29.5 million, compared to $30.2 million for the third quarter of 2023, showing a decline in revenue.
Gross-to-Net Discount Increase: The gross-to-net discount for XPOVIO in the third quarter of 2024 was 31%, compared to 21% in the third quarter of 2023, indicating increased pricing pressure.
R&D Expense Increase: R&D expenses for the third quarter of 2024 were $36.1 million compared to $35.6 million for the third quarter of 2023, reflecting rising costs in clinical trials.
SG&A Expense Management: SG&A expenses for the third quarter of 2024 were $27.6 million, compared to $30.8 million for the third quarter of 2023, indicating ongoing cost management efforts but still higher than expected.
KPTI FAQs
How does KPTI typically perform around its earnings report dates?
Is Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
KPTI Earning Call Sentiment
Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
KPTI.O
3.6%Positive
The earnings call reveals mixed financial performance with a slight revenue increase but declining cash reserves. Regulatory risks, competitive pressures, and supply chain challenges pose significant threats. The Q&A section indicates some positive clinical trial progress but lacks clarity on key metrics. Guidance remains unchanged, and no new partnerships were announced. These factors, combined with the absence of strong catalysts, suggest a negative stock price movement in the short term, particularly with financial stability concerns and competitive pressures in key markets.